Patent application number | Description | Published |
20090304191 | AUTOMATIC GAIN CONTROL SYSTEM APPLIED TO AN AUDIO SIGNAL AS A FUNCTION OF AMBIENT NOISE - An automatic gain control system applied to a audio signal as a function of the ambient noise, the system comprising: an ambient noise estimator module suitable for establishing a current noise value estimated at least from a signal provided by a microphone; and an automatic gain control module suitable for applying to the audio signal gain of a value that is determined as a function of the current noise value received from the ambient noise estimator module. According to the invention, the ambient noise estimator module comprises an MCRA estimator suitable for establishing the current noise value from a signal provided by the microphone picking up the real noise, the echo of the music, and where appropriate speech. The system also includes a module for estimating the power of the audio signal and suitable for providing the automatic gain control module with a current power value for the audio signal. | 12-10-2009 |
20090323983 | Method and a system for reconstituting low frequencies in audio signal - The method comprises the steps of: filtering the audio signal by means of a lowpass filter ( | 12-31-2009 |
20120163125 | METHOD OF ULTRASOUND TELEMETRY FOR DRONES, WITH DISCRIMINATION OF SPURIOUS ECHOES EMANATING FROM ANOTHER DRONE - The method comprises: a) the emission of an ultrasound burst repeated at a predetermined recurrence frequency; and b) after each emission and for the duration of a time frame (n−1, n, n+1, . . . ) separating two consecutive emissions, the reception of a plurality of successive signal spikes appearing in the course of the same frame. These spikes include spurious spikes (E′ | 06-28-2012 |
20130230191 | METHOD FOR ENHANCING LOW FREQUENCES IN A DIGITAL AUDIO SIGNAL - The method comprises the steps of: a) converting the digital audio signal (PCM) into a voltage signal (V | 09-05-2013 |
20140079256 | ONE-PIECE ACTIVE ACOUSTIC LOUDSPEAKER ENCLOSURE CONFIGURABLE TO BE USED ALONE OR AS A PAIR, WITH REINFORCEMENT OF THE STERO IMAGE - The loudspeaker enclosure ( | 03-20-2014 |
Patent application number | Description | Published |
20130132725 | PROTECTION METHOD, DECRYPTION METHOD, RECORDING MEDIUM AND TERMINAL FOR SAID PROTECTION METHOD - Protecting data transmission, either multimedia or a control word, between a security processor and a terminal includes, at the security processor, building a current session key by root key diversification as a function of a parameter transmitted by the terminal, decrypting the data, encrypting it with the session key, and transmitting it, and at the terminal, decrypting it using a secret code to obtain plain data, recording, in advance, secret codes, each enabling decryption of only data encrypted by a corresponding session key obtained by root-key diversification with a parameter, which can be the transmitted parameter, receiving the parameter in a message that also contains the data to be decrypted by the security processor, and in response, selecting, from the secret codes, a code for decrypting the data encrypted with the session key, as a function of the parameter or another parameter in the message. | 05-23-2013 |
Patent application number | Description | Published |
20090131636 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES - Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA. | 05-21-2009 |
20100003195 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY - The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K | 01-07-2010 |
20100008863 | TARGETING AND THERAPEUTIC COMPOUNDS AND GAS-FILLED MICROVESICLES COMPRISING SAID COMPOUNDS - New targeting or therapeutic compounds which can be incorporated into a composition of gas-filled microvesicles. The invention further relates to gas-filled microvesicles for diagnostic and/or therapeutic use comprising said compounds and to their method of use. The new compounds are compounds of formula M-S-T, wherein: M represents a component capable of associating with an envelope of a gas-filled microvesicle; T represents a component comprising a targeting ligand or a therapeutic agent; and S represents a component comprising at least two bissulfone groups. | 01-14-2010 |
20100158814 | Fibrin-Binding Peptides and Conjugates Thereof - Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging., etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof. | 06-24-2010 |
20100233090 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES - Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA. | 09-16-2010 |
20110070165 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS - The invention provides compositions and methods for therapeutic and diagnostic applications. | 03-24-2011 |
20110097275 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY - The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K | 04-28-2011 |
20110286936 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES - Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA. | 11-24-2011 |
20120328512 | Fibrin-Binding Peptides and Conjugates Thereof - Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging, etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof. | 12-27-2012 |
20130266519 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES - Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA. | 10-10-2013 |
20140031520 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES - Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA. | 01-30-2014 |
20140161732 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY - The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K | 06-12-2014 |
20140206837 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES - Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA. | 07-24-2014 |
20140286864 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY - The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K | 09-25-2014 |